Replimune Group (NASDAQ:REPL) Given “Buy” Rating at HC Wainwright

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 45.42% from the stock’s previous close.

A number of other brokerages have also issued reports on REPL. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Performance

Shares of REPL opened at $11.69 on Tuesday. The firm has a market cap of $798.66 million, a P/E ratio of -3.83 and a beta of 1.19. Replimune Group has a twelve month low of $4.92 and a twelve month high of $12.97. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The firm’s 50 day moving average price is $11.44 and its two-hundred day moving average price is $9.50.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. On average, analysts forecast that Replimune Group will post -3.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 8.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in Replimune Group during the first quarter worth approximately $927,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Replimune Group in the first quarter valued at approximately $1,088,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares during the period. Millennium Management LLC increased its holdings in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after acquiring an additional 53,313 shares during the period. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.